Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mitoxantrone

Next Previous
Search
Drug Profile

Mitoxantrone

Alternative Names: CL 232315; DHAD; DHAQ; dihydroxyanthracenedione; mitozantrone; Novantron; Novantrone; NSC 279836; NSC 301739; Onkotrone; Pralifan

Latest Information Update: 06 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wyeth
  • Developer Amgen; Pfizer; Takeda
  • Class Anthraquinones; Antineoplastics; Small molecules
  • Mechanism of Action DNA inhibitors; DNA topoisomerase inhibitors; Immunosuppressants; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia; Acute nonlymphocytic leukaemia; Acute promyelocytic leukaemia; Breast cancer; Cancer; Cancer pain; Leukaemia; Liver cancer; Multiple sclerosis; Non-Hodgkin's lymphoma; Ovarian cancer

Most Recent Events

  • 19 Apr 2024 University of Washington in collaboration with AbbVie suspends phase I trial in phase I trial for acute myeloid leukaemia (Combination therapy, Second-line or greater therapy) in USA (IV) due to phase transition/study design changes (NCT04797767)
  • 12 May 2023 University of Washington in collaboration with AbbVie suspends phase I trial in phase I trial for acute myeloid leukaemia (Combination therapy, Second-line or greater therapy) in USA due to pending protocol amendment (IV) (NCT04797767)
  • 29 Nov 2021 University of Washington in collaboration with AbbVie initiates enrolment in a phase I trial for acute myeloid leukaemia (Combination therapy, Second-line or greater therapy) in USA (IV) (NCT04797767)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top